Commit Biologics announces final close of $60 million seed financing to advance complement-powered immune engagers toward the clinic
News originally published by
GlobeNewswire- The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, alongside existing investors Bioqube Ventures, Korys and Novo Holdings
- Funds will take first development candidate COM002 into the clinic, advance a second program into IND-enabling development and expand the BiCE™ pipeline
-
Michael Rosenzweig (AbbVie Ventures), Charlotte Kremers (M Ventures) and Lenny Van Steenhuyse (Ackermans & van Haaren) join the Board of Directors
COPENHAGEN, Denmark, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, today announced the completion of a $60 million (€54 million) seed financing round to advance its pipeline of complement-powered immune engagers toward the clinic. The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, and existing investors Bioqube Ventures, Korys and Novo Holdings.
Proceeds from the financing will support the completion of IND-enabling activities and IND filing for COM002, Commit’s first development candidate, which was announced last week. COM002 is a dual-targeting Bispecific Complement Engager (BiCE™) molecule designed for targeted immune cell depletion, developed for patients with cancer and autoimmune disease. Additionally, the financing will advance a second program into IND-enabling development and expand Commit’s BiCE™ pipeline.
“Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy,” said Dr. Thomas L. F. Montgomery Andresen, CEO of Commit Biologics.
He added: “Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team.”
Charlotte Kremers, Principal at M Ventures, said: “Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.”
Lenny Van Steenhuyse, Investment Manager at Ackermans & van Haaren, added: “We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realize the full potential of the BiCE™ platform.”
For more information, please contact:
Optimum Strategic Communications
Nick Bastin, Stephen Adams, Aoife Minihan
Tel: +44 (0) 204 566 8543
Email: commit@optimumcomms.com
About the BiCE™ platform
Commit’s proprietary BiCE™ platform turns IgG antibodies into complement-powered immune engagers. BiCE™ antibodies are designed to recruit the complement protein C1q to induce rapid and selective elimination of targeted diseased cells through a T cell-independent mechanism. The platform taps into one of nature’s most ancient defense mechanisms, while retaining the properties of a conventional IgG antibody.
About Commit Biologics
Commit Biologics is developing complement-powered immune engagers, a new class of immunotherapies for autoimmune disease, oncology and beyond. Founded as a spin-out from Aarhus University, a long-standing internationally recognized hub for complement research, Commit is today based in Copenhagen and Aarhus. The company is backed by Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. www.commitbio.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.